Efficacy and Toxicity of Immune -Checkpoint Inhibitors in Patients With Preexisting Autoimmune Disorders

Complete response of metastatic melanoma in a patient with Crohn’s disease simultaneously receiving anti-α4β7 and anti-PD1 antibodies

(2019) Christopher C. Frohne et al.   Journal for ImmunoTherapy of Cancer

Interactions of HLA-DR and Topoisomerase I Epitope Modulated Genetic Risk for Systemic Sclerosis

(2019) Sirilak Kongkaew et al.   Scientific Reports

Clinical Outcomes of Patients with Advanced Cancer and Pre‐Existing Autoimmune Diseases Treated with Anti‐Programmed Death‐1 Immunotherapy: A Real‐World Transverse Study

(2019) Alessio Cortellini et al.   ONCOLOGIST

Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition

(2019) Vylyny Chat et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer

(2019) Kenneth L. Kehl et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Immune checkpoint inhibitor use in antisynthetase syndrome

(2019) David Mackintosh et al.   Asia-Pacific Journal of Clinical Oncology

Real-world outcomes of patients with advanced non-small cell lung cancer (aNSCLC) and autoimmune disease (AD) receiving immune checkpoint inhibitors (ICIs).

(2019) Sean Khozin et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and efficacy of PD-1 inhibitors in non–small cell lung cancer patients positive for antinuclear antibodies

(2019) Yasuto Yoneshima et al.   LUNG CANCER

Anti‐PD‐1 Immunotherapy‐Induced Flare of a Known Underlying Relapsing Vasculitis Mimicking Recurrent Cancer

(2019) Christopher S. Nabel et al.   ONCOLOGIST

Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?

(2019) Anne Zaremba et al.   Journal for ImmunoTherapy of Cancer

Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus

(2019) Marco Tagliamento et al.   Immunotherapy

Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies

(2019) T. Sakakida et al.   Clinical & Translational Oncology

Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders

(2018) Katharina C. Kähler et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease

(2018) François-Xavier Danlos et al.   EUROPEAN JOURNAL OF CANCER

Safety of Programmed Death–1 Pathway Inhibitors Among Patients With Non–Small-Cell Lung Cancer and Preexisting Autoimmune Disorders

(2018) Giulia C. Leonardi et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

(2018) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Brief Report: Cancer Immunotherapy in Patients With Preexisting Rheumatic Disease: The Mayo Clinic Experience

(2018) Michael D. Richter et al.   Arthritis & Rheumatology

Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer

(2018) Koji Haratani et al.   JAMA Oncology

PD-1 Inhibitor Immune-Related Adverse Events in Patients with Preexisting Endocrine Autoimmunity

(2018) Halis Kaan Akturk et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors

(2018) Omar Hasan Ali et al.   EUROPEAN JOURNAL OF CANCER

Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity

(2017) Ralf Gutzmer et al.   EUROPEAN JOURNAL OF CANCER

Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 5: Neurological auto-antibodies, discussion, flow chart, conclusions

(2017) Claudine Sculier et al.   LUNG CANCER

Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature Part 4: Neurological paraneoplastic syndromes, involving the peripheral nervous system and the neuromuscular junction and muscles

(2017) Lucien Ruelle et al.   LUNG CANCER

Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature

(2017) Stéphane Holbrechts et al.   LUNG CANCER

Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature

(2017) Georgiana Bentea et al.   LUNG CANCER

Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature

(2017) Valérie Durieux et al.   LUNG CANCER

The safety of pembrolizumab in metastatic melanoma and rheumatoid arthritis

(2017) Akshjot Puri et al.   MELANOMA RESEARCH

Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade

(2017) Khashayar Esfahani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Exacerbation of Psoriasis During Nivolumab Therapy for Metastatic Melanoma

(2016) N Matsumura et al.   ACTA DERMATO-VENEREOLOGICA

CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis

(2016) Lisa Ann Gerdes et al.   ANNALS OF NEUROLOGY

The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma

(2016) B. Lee et al.   ANNALS OF ONCOLOGY

Vasculitic neuropathy induced by pembrolizumab

(2016) F. Aya et al.   ANNALS OF ONCOLOGY

Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn’s disease: a case report

(2016) Marc Uemura et al.   Journal of Hematology & Oncology

Severe Psoriasis Flare After Anti-Programmed Death Ligand 1 (PD-L1) Therapy for Metastatic Non–Small Cell Lung Cancer (NSCLC)

(2016) Puey Ling Chia et al.   JOURNAL OF IMMUNOTHERAPY

Successful Anti-PD-1 Antibody Treatment in a Metastatic Melanoma Patient With Known Severe Autoimmune Disease

(2016) Lara V. Maul et al.   JOURNAL OF IMMUNOTHERAPY

Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab

(2016) K. H. Vincent Lau et al.   MUSCLE & NERVE

Myasthenia gravis exacerbation associated with pembrolizumab

(2016) Julia Zhu et al.   MUSCLE & NERVE

The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation

(2016) Kankana Bardhan et al.   Frontiers in Immunology

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

(2016) Douglas B. Johnson et al.   JAMA Oncology

Prevalence of Autoimmune Disease Among Patients With Lung Cancer

(2016) Saad A. Khan et al.   JAMA Oncology

Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid

(2016) Kristen M. Beck et al.   Journal for ImmunoTherapy of Cancer

Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes

(2015) M. Freeman-Keller et al.   CLINICAL CANCER RESEARCH

Serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab

(2015) Tomohiko Narita et al.   JOURNAL OF DERMATOLOGY

Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma

(2015) Y. Kato et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

High-density mapping of the MHC identifies a shared role for HLA-DRB1*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis

(2015) Philippe Goyette et al.   NATURE GENETICS

HLA-DRB1*11and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis

(2015) Michael J. Ombrello et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis

(2015) A Doran Bostwick et al.   Journal for ImmunoTherapy of Cancer

Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease

(2014) Magnus Pedersen et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Ipilimumab in a patient with known Crohn's disease: To give or not to give?

(2014) Eric A.R. Gielisse et al.   Journal of Crohns & Colitis

Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma

(2014) Edward J Gettings et al.   Multiple Sclerosis Journal

Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations

(2014) Desirée Schubert et al.   NATURE MEDICINE

Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4

(2014) H. S. Kuehn et al.   SCIENCE

Ipilimumab in patients with melanoma and autoimmune disease

(2014) Chrisann Kyi et al.   Journal for ImmunoTherapy of Cancer

Melanoma-Associated Retinopathy Treated with Ipilimumab Therapy

(2013) A. Audemard et al.   DERMATOLOGY

TheHLA-DRB1Polymorphism is Associated With Atopic Dermatitis, but not Egg Allergy in Korean Children

(2012) Hwayoung Park et al.   Allergy Asthma & Immunology Research

The role of the PD-1 pathway in autoimmunity and peripheral tolerance

(2011) Brian T. Fife et al.   Annals of the New York Academy of Sciences